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Review Article
The clinical benefits of real-time continuous glucose moni-
toring (rtCGM) use have been well demonstrated in both 
CSII- and MDI-treated T1D individuals; however, few 
studies have specifically looked at how individuals utilize 
rtCGM data.1,2 Although CGM management algorithms 
were established for subjects in clinical trials,3-5 recom-
mendations for patient use of rtCGM in everyday life situ-
ations are lacking.
The purpose of this article is to provide guidance to cli-
nicians and patients with type 1 diabetes (T1D) in effective 
use of rtCGM data, including glucose rate of change (ROC) 
arrows, for insulin dosing adjustments and other treatment 
decisions. The recommendations presented here are based 
both on our own clinical experiences as endocrinologists 
and our personal experiences living with T1D using rtCGM. 
Our recommendations also are based on findings from a 
recent survey1 we conducted to explore how 222 individu-
als with T1D used rtCGM successfully, defined as having a 
good A1c and minimal hypoglycemia, in their everyday 
self-management. Findings from the survey will be dis-
cussed throughout the article. It is important to note that the 
recommendations presented here are specific to the Dexcom 
Platinum G4 and G5 Mobile (Dexcom Inc, San Diego, CA, 
USA), both of which use the Software 505 algorithm. 
However, these recommendations can be adapted to other 
rtCGM systems.
Background
SMBG is recognized as a core component of effective self-
management of insulin-treated diabetes.6-10 However, given 
the recent advances in the accuracy, reliability, and usability 
of rtCGM systems that have alerts and ROC arrows, many 
clinicians and patients feel strongly that SMBG does not pro-
vide adequate information to effectively manage insulin-
treated diabetes to avoid extreme hyperglycemia and 
safeguard against hypoglycemia, which remains an ongoing 
threat to personal safety and well-being.11-16
Whereas SMBG presents only a single point-in-time mea-
sure of glucose, rtCGM displays continuous information 
about the current glucose level and glucose trends, and pro-
vides the user with ROC arrows, which indicate the direction 
and velocity of changing glucose. Another key feature differ-
entiating rtCGM from SMBG is the ability to program alerts 
that warn the user when glucose levels increase or decrease 
beyond a defined glycemic threshold, individualized for each 
patient. The around-the-clock vigilance with rtCGM provides 
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a significant safety advantage relative to SMBG and other 
technologies that do not automatically alert the patient if the 
glucose values go above or below a predetermined level.
Historically, rtCGM users have been instructed to verify 
their glucose value with SMBG before taking insulin or 
adjusting other components of therapy. Currently, all rtCGM 
systems in the United States are still indicated for “adjunctive 
use” with SMBG, which simply means that patients are 
always encouraged to confirm their CGM result with a finger-
stick test before making management decisions. However, the 
accuracy of some current rtCGM systems is now at levels 
similar to SMBG,17 and a growing body of evidence shows 
that use of glucose data (with MARD <10%) in combination 
with ROC arrows and alerts/alarms largely mitigates potential 
hypoglycemia risks associated with rtCGM-based dosing 
decisions and often improve glycemic outcomes.18,19 One 
rtCGM system (G5 Mobile, Dexcom, Inc, San Diego, CA) 
recently received CE-mark approval to replace SMBG for 
routine diabetes treatment decisions outside the United States. 
Recent in silico studies support this indication.19-21 However, 
regardless of the status of this indication to replace SMBG 
confirmatory results, patients are currently using these 
devices to make many treatment decisions.1 It is our clinical 
experience, however, that patients started on these devices are 
given instructions on how to wear them (calibrations, apply-
ing the sensor, day to day wear, etc), but they are provided 
little to no guidance on how to use the information they pro-
vide. Providers may review the data retrospectively and hope 
to identify patterns, but little information is provided on how 
to respond to the information in real-time. Moreover, several 
studies have demonstrated that use of professional (blinded) 
CGM does not confer significant benefits in improving 
patient care.22-25 Given that the majority of clinical benefits 
associated with CGM use come from real-time treatment 
decisions, we feel strongly that general guidelines on how to 
use real-time CGM should be provided to patients.
Evidence for Efficacy of rtCGM Use
Numerous studies have shown that use of real-time rtCGM 
improves glycemic control as measured by HbA1c, improves 
time in range, reduces hypoglycemia, and improves quality 
of life in both children and adults with T1D.26-35 However, 
the benefit of rtCGM is primarily seen in patients who regu-
larly wear their devices and appropriately utilize the glucose 
data provided.26,27 Interestingly, many studies have reported 
that rtCGM users performed SMBG notably less frequently 
than non-rtCGM users,27,30,32,36 A recent survey of 1613 
rtCGM users who are enrolled in the T1D Exchange registry 
found that approximately 50% of respondents performed 
SMBG “less often” or “much less often” when using 
rtCGM.29 This suggests that patients are currently relying on 
their rtCGM data to make therapy decisions including dosing 
timing and adjustments, diet modifications, and exercise tim-
ing and intensity in real-time.
As mentioned earlier, we conducted a survey of 222 T1D 
individuals who were successfully using rtCGM; success was 
defined as “minimal hypoglycemia, no severe hypoglycemia” 
and good glycemic control (mean HbA1c 6.9%), and found 
that they rely on their rtCGM system features, particularly the 
alerts and glucose ROC arrows, when making insulin dosage 
adjustments.1 Survey respondents reported that use of ROC 
arrows prompted significantly greater dosage adjustments 
(increases and reductions), resulting in improved HbA1c and 
reduced frequency/severity of both hyperglycemia and hypo-
glycemia. These dosage adjustments were significantly 
greater than the 10-20% adjustments in insulin dosing used in 
the JDRF Trial, DirecNet trial, and other studies.3-5
In stark contrast, when survey respondents were provided a 
situation with a current glucose of 220 mg/dl that was rapidly 
increasing (2 arrows up), they reported a dramatic 140% mean 
increase in their typical correctional insulin dose. With the 
same glucose level (220 mg/dl), subjects would decrease their 
dose by mean 42% in response to a falling glucose (2 arrows 
down). Therefore, with the same blood glucose value, insulin 
doses varied significantly, depending on the trend, ranging 
from 1.6-6.7 units. It is important to note that this survey was 
not intended to elucidate the “right” answer, but rather to iden-
tify the gap in our current clinical care and knowledge of patient 
behaviors. Patients are using these devices to make major 
changes in their insulin dose, yet no guidance is given to them. 
Therefore, there is a clear need to provide a framework to 
patients and clinicians on how to make these adjustments.37
Using rtCGM Data for Insulin Dosing 
Decisions
Important Conceptual Shift in Treatment 
Decision Making
Utilizing rtCGM data for therapy adjustment requires a con-
ceptual shift from “point-in-time” testing (SMBG) to “antici-
pated” glucose levels, using the glucose goal, current 
glucose value, trend graph, actionable alerts and ROC 
arrows. Figure 1 provides an example of how these compo-
nents appear in the rtCGM display. Note that these compo-
nents are not standardized among rtCGM systems. For 
example, among the 3 commercially rtCGM systems avail-
able worldwide that offer ROC arrows, there are differences 
in how ROC is defined and displayed (Figure 2). Again, the 
recommendations included in this article are based on the 
ROC arrows utilized in the Dexcom rtCGM systems. 
Therefore, it is very important that users and their clinicians 
become familiar with these differences when choosing an 
rtCGM device or switch from one system to another.
Utility of ROC Arrows
As discussed previously, rtCGM-based therapy adjustments 
should focus on the anticipated glucose by using the ROC 
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arrows in addition to the current glucose level. Calculations 
of insulin dosages are then based on the anticipated glucose 
and each user’s individualized glucose goals and insulin 
parameters, such as insulin-to-carbohydrate ratios (ICR) and 
insulin sensitivity factors (ISF), often referred to as “correc-
tion factor” (CF). For example, if the rtCGM displayed a glu-
cose value of 120 mg/dl with 1 up ROC arrow, the anticipated 
glucose would be between 180 mg/dl and 210 mg/dl in 30 
minutes. The calculated insulin dose would then be based on 
this anticipated glucose range. The 30-minute time frame 
was selected because the pharmacokinetics and pharmacody-
namics of current rapid acting insulin analogues require 
roughly this amount of time to meaningfully affect glucose 
levels. In our experience, the trend information is reliable in 
predicting a glucose 30 minutes in the future.
An easy way to determine the 30-minute anticipated glu-
cose is to use the calculations presented in Figure 3. For exam-
ple, if the rtCGM displays the current glucose as 120 mg/dl 
with 1 UP ROC arrow, the insulin dosage would be based on 
an anticipated, 30-minute glucose of 180 mg/dl (most conser-
vative approach). The user can decide based on other variables 
mentioned below to use the higher target (up to 210 mg/dl).
This method allows for appropriate (albeit conservative) 
treatment decision-making given the numerous factors that 
can affect the degree and duration of glucose excursions. For 
example, it is known that subcutaneous injections of identi-
cal insulin doses in the same body location can lead to con-
siderable intra- and interindividual differences in glycemic 
response.38 Studies have also shown that analog insulin 
absorption and activity with CSII varies significantly over 3 
days of continuous infusion.39-42 Table 1 presents some of the 
main variables to consider when using ROC arrows to calcu-
late insulin dosages.
Although accurate prediction of an exact glucose level at 
any future time is unrealistic, the anticipated 30-minute glu-
cose range indicated by the ROC arrows provides a narrow 
enough estimate to make appropriate treatment decisions. An 
alternative method of insulin adjustment would be to use a 
percentage increase or decrease depending on the ROC curve 
as we reported in our initial survey, however we felt using 
the anticipated glucose method would be simpler and easier 
to use.
Moreover, because rtCGM provides continuous feedback 
(eg, alerts, trending and current glucose data), the user has 
the ability to “fine-tune” treatment as needed and make any 
follow-up adjustments if the dose given was too high or too 
low. However, users should be cautioned about stacking their 
doses (taking multiple boluses too close together in time). If 
a user gives a correction dose within 2 hours of the last bolus, 
the risk of hypoglycemia is increased because subcutane-
ously delivered rapid-acting insulin can take up to 90-120 
minutes to peak and may still be working 4 to 5 hours after 
the injection. The time course of action of rapid acting insu-
lin will vary from patient to patient and from day to day, and 
needs to be individualized. One set of recommendations does 
not apply to all, and this is especially true when it comes to 
calculating insulin doses in T1D. Although patient education 
can provide the principles of intensive insulin management, 
the most effective learning will come from trial and error and 
user experience over time. Wearing a CGM continuously 
protects the user from “mistakes” and the unpredictable 
nature of insulin pharmacodynamics.
Clinical Scenarios
The following scenarios represent examples of how ROC 
arrows can be used for both prandial and correction dosing, 
using the glucose percentage method. The insulin parameters 
used for the scenarios are 110 mg/dl for target glucose; 1:15 
grams insulin-to-carbohydrate ratio (I:CHO); and a CF of 
1:50 mg/dl. The planned meal for the prandial dosing sce-
narios is 45 g carbohydrate.
Prandial Dosing With Angle UP ROC Arrow. As shown in the 
rtCGM display, the current glucose is at target with an angle-
up ROC arrow (Figure 4). Using the simpler method, the 
patient would calculate the 30-minute anticipated glucose to 
be 160 mg/dl. The first step in prandial dosing is to calculate 
the insulin dose needed to cover the planned carbohydrate 
Figure 1. Data components of rtCGM-based therapy 
adjustments. (A) Current glucose: The rtCGM displays the 
current sensor glucose as a numerical value. (B) Trend graph: The 
rtCGM systems display trend graphs that visualize glucose levels 
over the past 1-24 hours. This information provides information 
that can help users prevent recurrence of specific problems. (C) 
Rate of change (ROC) arrows: The ROC arrows indicate the 
direction and rate of change (increase/decrease) within a specified 
time period. Note that the current commercially available rtCGM 
systems use slightly different arrow configurations and time 
periods.
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intake, which, in this case, would be 3.0 units. The next step 
is to calculate the insulin needed to cover the 30-minute 
anticipated glucose, which would be 1.0 units. Therefore, the 
total prandial dose would be 4 units, depending on other vari-
ables that the patient should consider discussed in Table 1. 
The process is easier for insulin pump users, who would sim-
ply enter the anticipated CHOs and selected 30-minute antic-
ipated glucose. The bolus calculator will then determine the 
insulin dose. As previously mentioned, there are now a glu-
cose meter and phone apps that can make the same bolus 
calculations with more coming on the market almost daily.
It is important to note that in this particular situation, even 
taking the most “extreme” adjustment recommended would 
be an increase in dose by 1.2 units. We feel that these recom-
mendations are a conservative starting point that can then be 
adjusted based on postprandial results. The key message, 
however, is that patients need to understand the concept that 
blood glucose numbers are not static, and, therefore, dosing 
for anticipated changes is required. It is for this reason that 
mealtime dosing with analogue insulin is advised 20 minutes 
before eating.
In situations where the glucose is rising more rapidly (1 or 
2 UP arrows), it is sometimes recommended that the patient 
administer the insulin but wait to eat the meal until the ROC 
arrows start to angle or level off, indicating the rate of change 
of glucose is slowing down. This strategy is referred to as 
“waiting for the bend” on the CGM display, which indicates 
insulin action. Patients can be instructed to use this as a cue 
for timing of meals.43 Early administration of prandial insu-
lin and waiting to consume the meal has been shown to 
reduce the post meal glucose level and negate the need for a 
correction dose, thereby minimizing the risk of insulin 
“stacking” and delayed hypoglycemia.44
Prandial Dosing With Angle DOWN ROC Arrow. In this sce-
nario, the rtCGM shows that the current glucose is at target 
(110 mg/dl) with the angle DOWN arrow (Figure 5). The 
patient would calculate the 30-minute anticipated glucose, 
which in this case would be 60 mg/dl. The patient would 
calculate the insulin needed to cover the planned carbohy-
drate intake (3.0 units). However, in situations such as this, 
in which the expected glucose trend could take this patient 
into a hypoglycemic level, patients are advised to eat the 
meal first and closely monitor the glucose trend to confirm 
mitigation of the impending hypoglycemia. Insulin may or 
may not be needed depending on the size and nutrient com-
position of the meal, the amount of insulin onboard, the cur-
rent glucose level, and the rate of glucose fall. Therefore, in 
Figure 2. System differences in ROC arrows.
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some situations, it is advised that the patient eat first and 
then, wait for the glucose to stabilize, and then administer 
insulin only if the glucose begins to rise or stabilizes (hori-
zontal ROC arrow) at a higher then desired level.
It is important to note that in the 2 prandial scenarios dis-
cussed, not only did the insulin dose recommendations 
change (ranging from adding a correction component to no 
correction) but so did the meal timing (ranging from waiting 
to eat to eating immediately). Notably, in each situation, the 
current blood glucose level was identical (110 mg/dl), yet the 
management recommendations are drastically different, 
again highlighting the importance of ROC information.
Correction Dosing With 1 UP ROC Arrow. In this scenario, the 
rtCGM shows that the current glucose is 220 mg/dl with 1 
UP arrow (Figure 6). This indicates a 30-minute anticipated 
glucose of 295 mg/dl, using the simpler method. Based on 
the CF of 1:50 with a goal of 110 mg/dl, the patient would 
give a correctional dose of 3.7 units to achieve the glucose 
target of 110 mg/dl. Insulin pump users simply enter the 
30-minute anticipated glucose into their pump and the cor-
rection dosage will be calculated automatically. Had this 
patient used the static glucose value of 220 mg/dl alone 
(horizontal ROC arrow), the calculated dose would be 2.2 
units. Therefore, this recommendation would result in a 
70% dose increase. We believe this is a conservative adjust-
ment based on our personal and clinical experience, as well 
as our survey results, which showed an average increase of 
110%. Another variable that should be considered by users 
is that when the glucose value is very high such as above 
(>300 mg/dl), they become resistant to the administered 
insulin and that their normal CF becomes inadequate. For 
example, one’s CF may be 1:50 mg/dl when the glucose 
value is below 250 mg/dl, however it changes to 1:35 mg/dl 
when the glucose value is above 250 mg/dl. Once again, 
Figure 4. 110 mg/dl with angle UP arrow (phone app display).
Figure 3. Flow sheet for prandial and correction dosages.
Table 1. Key Variables to Consider When Using ROC Arrows.
• Variability of insulin onset, peak action, and duration
• Impact of meal composition and portion size
•  Prior and anticipated exercise taking into account the 
duration and intensity
• Medications that raise the glucose values
• Stress level
• Illness
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Figure 6. 220 mg/dl with UP arrow (phone app display).
these variables affect each individual differently and it is 
impossible to come up with formal recommendations to fit 
all patients with diabetes.
Correction Dosing With 1 DOWN ROC Arrow. In this scenario, 
the rtCGM shows that the current glucose is 220 mg/dl with 
1 DOWN arrow (Figure 7). This indicates a 30-minute 
anticipated glucose of 145 mg/dl. In this situation, many 
patients would wait until the ROC arrow levels off (horizon-
tal) before giving additional insulin. If the arrow levels off 
above goal, the patient can then calculate and administer a 
correction dose accordingly. If the arrow levels off below 
the target range or does not level off, the patient should 
obviously take appropriate actions to prevent impending 
hypoglycemia. This example highlights, again, the impor-
tance of incorporating the ROC information, as in these 2 
correctional scenarios with identical glucose of 220 mg/dl, 
recommendations range from not taking any insulin to tak-
ing a larger than “usual” dose.
Practical Considerations
Although the above recommendations focus primarily on 
making insulin adjustments based on ROC arrows, it is 
important to note that these are intended only as a starting 
point. Multiple variables must be considered when deter-
mining whether and/or to what degree an insulin adjustment 
is warranted. These include but are not limited to:
•• Previous exercise: Patients will be more insulin sen-
sitive after exercise and may have to adjust their 
insulin needs on the more conservative side. In addi-
tion the intensity and duration of exercise performed 
in important. Walking for 30 minutes at a slow pace 
is obviously quite different than a 5-mile ocean 
swim.
•• Planned exercise: Depending on the duration and inten-
sity of exercise, this may lower or raise the patient’s 
glucose, especially after the exercise is concluded, and 
affect the insulin dosing. Users should be adjusting any 
Figure 5. 110 mg/dl with angle DOWN arrow (phone app 
display).
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prandial insulin dosing, nutrient consumption and basal 
rate alterations for pump users, and so on.
•• Meal composition (previous or planned): High CHO 
meals will affect the patient’s glucose immediately, 
and thus the above recommendations are probably the 
most accurate for CHO containing meals. However, 
high fat/protein meals have delayed absorption and 
lead to delayed hyperglycemia, meaning that insulin 
doses may have to be adjusted accordingly.44
•• Active insulin: The duration of rapid-acting insulin 
activity is generally 3-5 hours. When administering cor-
rection doses within this time period, patients must con-
sider this additional insulin action and, thus, consider 
reducing the correction dose. Otherwise, this can result 
in insulin “stacking,” which can lead to hypoglycemia.
Limitations of Dosing Adjustments Based on ROC 
Arrows
Although we have seen significant improvements in the 
accuracy rtCGM within the past few years, a few challenges 
remain that can impact sensor reliability and performance. In 
other words, there are situations when patients will need to 
confirm their rtCGM data with SMBG.
•• Use of acetaminophen. Acetaminophen treatment 
impacts rtCGM accuracy, resulting in erroneously 
high glucose readings and causing a falsely elevated 
ROC arrow.45 Use of acetaminophen can also cause a 
false increase in the rate of glucose change, affecting 
ROC arrows.
•• Symptoms do not match the rtCGM trend information. 
It is critical that patients perform a fingerstick test 
whenever their rtCGM data, such as the glucose value 
or trend information, do not match their symptoms or 
expectations. Patients also need to know that SMBG 
values also can be false, and hand washing before 
lancing the finger is strongly advised.
•• When trend graph is showing a change in glucose 
direction. The ROC arrows are based on the average 
rate of change over the preceding 20-30 minutes. If 
the trend graph shows a change in glucose direction, 
the dosing adjustments should not be based on the 
ROC arrows. For example, following treatment of 
hypoglycemia, the trend arrows, which had been 
pointing down, may lag behind the trend graph. So, 
although the glucose may be rapidly rising as seen 
on the trend graph, the trend arrows may be 
horizontal.
•• At initiation of rtCGM monitoring. Using the infor-
mation provided by these devices is a gradual learn-
ing curve. We do not advise patients to immediately 
begin following these recommendations until they 
are comfortable with the device and feel that the 
results accurately match their SMBG results. Once 
they gain confidence in their rtCGM data, they can 
begin using the information to make treatment 
decisions.
Users should be encouraged to think about their decisions 
that worked well and what they could do differently to pre-
vent high, low, or rapidly changing glucose. Table 2 presents 
additional advice and suggestions for safe and efficacious 
use of rtCGM.
Discussion
CGM has been available for over 10 years, and until now, 
there has been a scarcity of recommendations on how to 
adjust premeal and correction insulin doses based on the 
ROC or trend arrows. T1D is a condition in which many 
variables can affect glucose values. Thus, patients must 
experiment; “trial and error” is the norm rather than the 
exception.
Preventing the duration and severity of hyperglycemia, 
while avoiding hypoglycemia is the goal in T1D. We feel that 
the introduction of CGM is one of the most important 
Figure 7. 220 mg/dl with DOWN arrow (phone app display).
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advances for people with T1D since the discovery of insulin 
in the early 1920s.
The recommendations given in this article are primarily 
from our validated questionnaire of 222 successful rtCGM 
users (mean HbA1c of 6.9% with minimal, mild, and no 
severe hypoglycemia), but also from our own personal 
experience living with T1D for a combined 68 years, and 
from seeing patients in clinic as well as from the multiple 
large patient oriented conferences we present around the 
country (Taking Control of Your Diabetes, www.tcoyd.org).
Our idea of using the anticipated glucose in 30 minutes is 
a very straightforward and conservative approach to increas-
ing and decreasing the insulin does before meals and for cor-
rection. For example, the subjects in our survey made greater 
percentage changes in their dose based on the ROC arrows 
compared to the anticipated glucose method we have 
proposed.
The main point of our recommendations is to have users 
of rtCGM devices, and providers that prescribe them, start to 
think about these concepts and make adjustments in their 
diabetes management based on where their glucose values 
were coming from and the direction that they are going. 
Merely using a static glucose value to calculate insulin doses 
along with the grams of carbohydrates has limited value.
We do not think it is possible to give precise formulas 
for insulin dosing in people with T1D, but only general 
guidelines as a place to start from. It is also not feasible to 
provide exact recommendations for the many variables that 
can and commonly do affect glucose control, including the 
composition, amount and timing of food ingestion, exercise 
(type, timing, intensity, duration), prior insulin dose, other 
illnesses, other medications, stress, seasonal and diurnal 
variations in insulin sensitivity, mild to moderate gastropa-
resis, and so on. Added to these variables is the fact that 
subcutaneously injected insulin has a tremendous day-to-
day intrapatient variability that creates a greater degree of 
unpredictability.
It is our hope that our recommendations provide a starting 
point for how to use the trend information. More important 
than the specific recommendations is the concept that insulin 
doses must be modified based on this valuable trend infor-
mation. This concept applies not only to patients using these 
devices in real time but to the providers who will be guiding 
patients throughout the “lifespan” of these devices, from ini-
tiating use to perfecting it.
We believe that previous recommendations on insulin 
dosing have been far too rigid for far too long and fail to 
incorporate useful rtCGM information. As proof of this, our 
recommendations and previous work highlight that not all 
glucoses are created equal. Advice on how to respond to a 
given glucose value varies drastically based on where the 
glucose level is heading. If this information is not incorpo-
rated into insulin management, then we are not using these 
devices to their fullest potential, and in fact, missing their 
benefit entirely.
Having access to an accurate glucose value every 5 min-
utes with high and low alerts and ROC arrows is the most 
valuable tool people with type 1 diabetes have to help predict 
the unpredictable. We hope our recommendations to adjust 
insulin dosing based on the anticipated glucose in 30 minutes 
for mealtime and corrections will be helpful to people living 
with T1D and providers who take care of them.
Table 2. Advice and Recommendations for Safe, Effective rtCGM Use.
1.   Users should be encouraged to wear the rtCGM as much as possible and look at the receiver frequently. The clinical benefits of rtCGM are 
only realized with frequent, persistent use.
2.   Users should set reasonable expectations for their rtCGM. rtCGM is an excellent tool, but it is not perfect. It is important to calibrate as 
instructed by the manufacturer to minimize false readings and alarms.
3.   Confirmation with SMBG is sometimes needed. If the rtCGM device does not display a sensor glucose reading, ROC arrow or is 
displaying inconsistent readings, users should perform a fingerstick blood glucose value for diabetes treatment decisions. Fingerstick 
testing should also be performed if glucose alerts and readings do not match symptoms or expectations. This is especially critical at 
initiation of CGM monitoring.
4.   Alerts and alarms should be viewed as critical components of rtCGM use. Users should be encouraged to use the high and low alerts 
and modify them over time. However, setting the alarms too aggressively at initiation can result in alarm fatigue. Therefore, it is 
recommended that as control improves, the alarms can be narrowed to encourage tighter control.
5.   Users should have a plan for preventing or responding to low glucose. Users should be instructed to respond immediately to low glucose 
but not overreact. Users may not see the effects of treatment with carbohydrates for more than 15 minutes. In addition, as CGM 
devices alert caregivers, a discussion with friends and family on how to respond to alarms is encouraged.
6.   Respond to high glucose between meals but avoid “stacking” insulin. Constantly seeing high glucose values can lead to frustration and 
inclination to bolus repeatedly. Therefore, users should be reminded that rapid-acting insulin can take up to 90-120 minutes to 
peak and may still be working 3-5 hours after their last injection. Stacking insulin poses a high risk for hypoglycemia; whereas, 
administration of conservative insulin doses, guided by rtCGM data, mitigates this risk.
7.   Users should be encouraged to utilize the ROC information to make treatment decisions. As mentioned in this article, this trend affects 
meal timing, insulin dosing, and many other aspects of T1D management. Doing “correctly” takes time, but will come with 
experience and guidance from their clinician.
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